Navigation Links
UW launches study testing adult stem cells for heart damage repair

The University of Wisconsin School of Medicine and Public Health is among the first medical centers in the country taking part in a novel clinical trial investigating if a subject's own stem cells can treat a form of severe coronary artery disease.

The trial, just underway at UW Hospital and Clinics, is enrolling subjects in the Autologous Cellular Therapy CD34-Chronic Myocardial Ischemia (ACT34-CMI) Trial. The first patient underwent the procedure March 7. Because the study is randomized and "double-blinded," however, neither the patient nor the research physician knows if he received his own stem cells or a placebo substance.

This trial is the first human Phase II adult stem cell therapy study in the U.S. Its goal is to investigate the efficacy, tolerability, and safety of blood-derived selected stem cells to improve symptoms and clinical outcomes in patients with chronic myocardial ischemia (CMI), a severe form of coronary artery disease.

Myocardial ischemia, which affects hundreds of thousands of people, is a serious heart condition that involves narrowing of coronary arteries and results in limited blood flow to the heart. A person who suffers from chronic myocardial ischemia continues to experience insufficient flow of oxygen-rich blood to the heart despite optimum medical intervention.

This type of therapy - regenerative medicine - treats diseases by using growth factors, genes or stem cells to promote blood vessel or tissue growth," explains Amish Raval, head of cardiovascular regenerative medicine at UW Health.

The goal with this approach, he says, is to promote either angiogenesis, which is the growth of new capillaries; arteriogenesis, or the maturation and enlargement of existing arteries and arterioles; or vasculogenesis, the sprouting of new arteries and arterioles.

The stem-cell study is considered the "gold standard" of research design: a prospective, randomized, double-blind, placebo-controlled
'"/>

Source:University of Wisconsin-Madison


Page: 1 2 3

Related biology news :

1. UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders
2. UNC launches study of liver injury caused by drugs
3. DOE JGI launches IMG public online microbial genome data clearinghouse
4. NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina
5. NIH launches comprehensive effort to explore cancer genomics
6. Virginia Bioinformatics Institutes launches microbial database
7. BioMed Central launches Biology Direct
8. Protein structure initiative launches new resources for the scientific community
9. NIH neuroscience microarray consortium launches high-throughput genotyping services
10. ESA launches new project to protect biodiversity
11. Africas first large-scale HIV vaccine study launches

Post Your Comments:
(Date:11/25/2009)...ens, Ga. Bacteria don,t have easy lives. In addit...ugs, they have natural enemies called bacteriophag...very two days. , Still, bacteria and another cl...ered in extreme environments such as deep-sea volc...ecause they have a built-in defense system that he...
(Date:11/25/2009)...r. Sarit Larisch, Head of the Cell Death Research ... of Biology, has been awarded the prestigious John...ch exploring the cause of brain cell damage in Par... year to scientists in support of innovation and e...fficially conferred earlier this month at an event...
(Date:11/25/2009)...r the course of a lifetime, the heart pumps some 2...e order to do this, the muscle fibers of the heart...headed by Dr. Wolfgang Rottbauer, vice chair of th...ity Hospital (Chairman: Prof. Dr. H. A. Katus), ha... stability of the smallest muscular unit, the sarc...
Breaking Biology News(10 mins):Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2New genetic cause of cardiac failure discovered 2Halos of Hope ASTRO partner to raise awareness of cancer survivorship 59519 1 244 million NCI grant funds comparative effectiveness research at Southwest Oncology Group 59516 1 244 million NCI grant funds comparative effectiveness research at Southwest Oncology Group 59516 2 244 million NCI grant funds comparative effectiveness research at Southwest Oncology Group 59516 3Biomedical Research Centre searches for immunological biomarkers 59513 1Biomedical Research Centre searches for immunological biomarkers 59513 2
...hs of a vaccine designed to fight avian influenza ...enter. , The Duke study is part of a multicenter t...ational bird flu vaccine to determine whether the ... lower doses. , The seven-month trial is sponsor...ious Diseases of the National Institutes of Health...
...al Center study shows that exposure to environment... associated with behavior problems in children and...r olds with asthma, the findings most likely could...a who "act out" or experience depression and anxie...her at the Children,s Environmental Health Center ...
... aggressive, but may keep them that way into young...here may be other, lasting consequences for the de...uary,s Behavioral Neuroscience, also showed that a...itter levels in the brain,s aggression control reg...American Psychological Association (APA). , Neuros...
Other Biology News:Duke to test bird flu vaccine dosing 2Environmental tobacco smoke linked to behavior problems in children and pre-teens 2Animal models show that anabolic steroids flip the adolescent brain's switch for aggression 2Animal models show that anabolic steroids flip the adolescent brain's switch for aggression 3
(Date:11/24/2009)...REYKJAVIK,Iceland,November24/PRNewswire-FirstCall/...dtheapprovalofallofits,"firstday"motionsbytheU.S.B...ptcyCourt").deCODElastweekfiledavoluntarypetitionf...Codewiththe,BankruptcyCourt. , Theordersissue...perateitsbusinessduringtheChapter11proceedings.Inp...
(Date:11/24/2009)...SANMATEO,Calif.,Nov.24/PRNewswire-FirstCall/--Neur...yfocusedondevelopingandcommercializingnovelpainman...PresidentandChiefExecutiveOfficer,isscheduledtopre...e,tobeheldDecember1-2,2009atTheNewYorkPalaceHoteli...eri,ChiefFinancialOfficer,willbeavailabletorespond...
(Date:11/24/2009)...SEATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.a...opmentAuthority(OPDA)wererecentlyawarded$2millionb...oard(CERB)inaprivate/publicpartnershiptoconstructt...colnCounty,WA. ,, "Thisinvestmentwillsignifican...70greenjobstoLincolnCounty,"saidBlueMarbleEnergyCE...
(Date:11/24/2009)...Primaryefficacyendpointhasbeenmetforpatientswithad...QUEBECCITY,Nov.24/PRNewswire-FirstCall/-AEternaZen...obalbiopharmaceuticalcompanyfocusedonendocrinether...romaPhase2studywithitstargetedcytotoxicpeptideconj...cedorrecurrentendometrialcancer.Inapersonalizedhea...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...rve Pharmaceutical Partner Interest for ...., March 31 Transgenomic, Inc. (OTC,Bulletin Boar...ompany,today announced that it has entered into a ...amily Planning Center in Guangzhou, China. Under t...Guangzhou Laboratory to,provide pharmacogenomic an...
...n Medical, Inc., the,leading developer of stents d...n lesions announced today that it has closed a $14...stors, PTV Sciences and RiverVest Venture,Partners...ng. Rick Anderson,from PTV and Jay Schmelter from ...of Directors., "Bifurcation lesions are an import...
...peutics, a drug,and diagnostic discovery company, ... Jaskowiak will join the Management Board on April...l become President of the,Management Board, until ...rved as CFO of ExonHit Therapeutics since 2002,and...004. John Jaskowiak,who joined ExonHit in 2006, wa...
Other Biology Technology:Transgenomic Opens Pharmacogenomics Laboratory in China 2Transgenomic Opens Pharmacogenomics Laboratory in China 3Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3ExonHit Appoints a New Management Board 2ExonHit Appoints a New Management Board 3ExonHit Appoints a New Management Board 4
...apid-Screen cDNA Library Panels were designed for ...ts of PCRs to identify the desired cDNA clone. The...ter Plate," where each well contains plasmid DNA f...ell(s) by gel electrophoresis of the reaction prod...
...A Jobin Yvons Protein 295 ex can measure three flu...otein sample in only a few minutes. To match the a...ryptophan, the Protein 295 exs excitation source i... 295 nm. Fluorescence of tryptophan is widely used...
...arrays designed for proteomic scale kinase profili...ivities, and drug discovery research built on the ... synthesis platform. These microarrays are availab...strate - Peptide Microarray Service. Probe Conte...
...-7000 is a research grade spectrofluorometer which...dth and scanning speeds of up to 60,000nm/min. It...oncentrated light beam along with low sample volum...C fluorescence applications software, which offers...
Biology Products: